Tess Johnson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tess Johnson has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Euzebiusz Jamrozik
Ethox and Pandemic Sciences Institute, University of Oxford
3 shared publications - Diego Steven Silva
Sydney Health Ethics, School of Public Health, University of Sydney, Camperdown, Australia
2 shared publications - Gerald Owen Schaefer
National University of Singapore
2 shared publications - Jonathan D. Shaffer
University of Vermont, Burlington, United States
2 shared publications - Julian Savulescu
National University of Singapore
2 shared publications - Marlyn Faure
University of Oxford, Oxford, UK
2 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 6 March 2026
- Published by Taylor & Francis in The American Journal of Bioethics
- Vol. 26 (9) , 79-93
Ethics of Antibiotic Course Duration: Shorter is Better
Antibiotic treatment course duration has for decades been dictated by two questionable ideas: first, that longer courses are more effective at curing bacterial infections; second, that longer courses are less likely to lead to drug resistance. Recently, the "shorter is better" movement has challenged the received wisdom, showing shorter-duration antibiotic courses provide similar cure rates, fewer antibiotic-related harms, and possibly less contribution to of antibiotic resistance for common infections. Yet, physicians typically still prescribe longer courses of antibiotics than clinical guidelines recommend. This is ethically unacceptable. In this paper, we argue that prescribing physicians are ethically obligated to prescribe shorter antibiotic courses, given that prescribing physicians bear duties both toward their patients and to protect public health. We rebut objections to our argument and furthermore argue for an ethical obligation of physician-researchers to conduct further trials comparing the shortest current evidence-based course of antibiotics with courses that are even shorter.
- 6 March 2026
- Published by Taylor & Francis in The American Journal of Bioethics
- Vol. 26 (9) , 79-93
Top Cited PapersOpen AccessEthics of Antibiotic Course Duration: Shorter is Better
Antibiotic treatment course duration has for decades been dictated by two questionable ideas: first, that longer courses are more effective at curing bacterial infections; second, that longer courses are less likely to lead to drug resistance. Recently, the "shorter is better" movement has challenged the received wisdom, showing shorter-duration antibiotic courses provide similar cure rates, fewer antibiotic-related harms, and possibly less contribution to of antibiotic resistance for common infections. Yet, physicians typically still prescribe longer courses of antibiotics than clinical guidelines recommend. This is ethically unacceptable. In this paper, we argue that prescribing physicians are ethically obligated to prescribe shorter antibiotic courses, given that prescribing physicians bear duties both toward their patients and to protect public health. We rebut objections to our argument and furthermore argue for an ethical obligation of physician-researchers to conduct further trials comparing the shortest current evidence-based course of antibiotics with courses that are even shorter.
- Open Access
- 4 March 2026
- Published by Elsevier in The Lancet Microbe
- Vol. 7 (6) , 101372
The role of microbial genomics in delivering the UK’s national action plan for confronting antimicrobial resistance 2024–29
- 4 March 2026
- Published by Elsevier in The Lancet Microbe
- Vol. 7 (6) , 101372
Open AccessThe role of microbial genomics in delivering the UK’s national action plan for confronting antimicrobial resistance 2024–29
- Top Cited PapersOpen Access
- 27 February 2026
- Published by Taylor & Francis in The American Journal of Bioethics
- Vol. 26 (11) , 39-52
Beyond Good and Bad: Rethinking Solidarity and Coercion in Public Health
Public health policy makers, practitioners and researchers—including ethicists—use certain terms as if the moral valence of said terms is set, well-understood, or shared by various actors. For exam...
- 27 February 2026
- Published by Taylor & Francis in The American Journal of Bioethics
- Vol. 26 (11) , 39-52
Top Cited PapersOpen AccessBeyond Good and Bad: Rethinking Solidarity and Coercion in Public Health
Public health policy makers, practitioners and researchers—including ethicists—use certain terms as if the moral valence of said terms is set, well-understood, or shared by various actors. For exam...
- Open Access
- 17 October 2025
- Published by Cambridge University Press (CUP) in Public Humanities
- Vol. 1, e148
A Just Transition for Antimicrobial Resistance: The Need for More Forms and a Broader Scope of Justice
Antimicrobial resistance (AMR) is a global public health challenge that, like climate change, demands urgent, coordinated, multi-sectoral action. Yet, responses to AMR may be ill-suited to local contexts, overlook historical inequalities, or dismiss marginalised knowledge systems. Some of these concerns can be discussed using the concept of a just transition, which aims to ensure that “no one is left behind,” “all voices are heard,” and past injustices are addressed. However, framing justice in these terms is insufficient. We argue for a more multifaceted and broader-scoped understanding of what justice demands in a just transition for AMR. We examine existing justice frameworks in AMR literature and discuss two cases that motivate our call for including both more forms of justice in a multifaceted concept of a just transition and a broader scope of justice. The first case involves over-the-counter antibiotic access in the Kibera informal settlement near Nairobi, highlighting structural injustices resulting from colonial oppression and what an Ubuntu philosophy would show as injustice. The second case concerns veterinary prescription requirements for Maasai pastoralists’ livestock farming in southern Kenya and highlights epistemic and distributive injustices, as well as injustices that befall non-human animals. These examples reveal distinct injustices shaped by socio-cultural and ecological contexts.
- 17 October 2025
- Published by Cambridge University Press (CUP) in Public Humanities
- Vol. 1, e148
Open AccessA Just Transition for Antimicrobial Resistance: The Need for More Forms and a Broader Scope of Justice
Antimicrobial resistance (AMR) is a global public health challenge that, like climate change, demands urgent, coordinated, multi-sectoral action. Yet, responses to AMR may be ill-suited to local contexts, overlook historical inequalities, or dismiss marginalised knowledge systems. Some of these concerns can be discussed using the concept of a just transition, which aims to ensure that “no one is left behind,” “all voices are heard,” and past injustices are addressed. However, framing justice in these terms is insufficient. We argue for a more multifaceted and broader-scoped understanding of what justice demands in a just transition for AMR. We examine existing justice frameworks in AMR literature and discuss two cases that motivate our call for including both more forms of justice in a multifaceted concept of a just transition and a broader scope of justice. The first case involves over-the-counter antibiotic access in the Kibera informal settlement near Nairobi, highlighting structural injustices resulting from colonial oppression and what an Ubuntu philosophy would show as injustice. The second case concerns veterinary prescription requirements for Maasai pastoralists’ livestock farming in southern Kenya and highlights epistemic and distributive injustices, as well as injustices that befall non-human animals. These examples reveal distinct injustices shaped by socio-cultural and ecological contexts.
- Open Access
- 3 August 2025
- Published by BMJ in BMJ Global Health
- Vol. 10 (8) , e018943
A just war on bugs? Ethical differences between antimalarial resistance and antibacterial resistance
Antimicrobial resistance (AMR) refers to the ability of microbes—bacteria, viruses, fungi and parasites—to survive exposure to drugs that previously cleared them. Mostly, assessments of AMR in research papers and high-level policy documents focus on antibacterial resistance (ABR), sidelining viruses, fungi and parasites. For instance, we know that in 2019 ABR caused around 1.27 million deaths and was associated with 4.95 million deaths. 1 We do not know how many further deaths were associated with or attributable to fungal, parasitic or viral AMR. AMR has negative implications for humans, animals and the environment, including increased morbidity and mortality and unbalanced ecosystems.2 AMR’s effects in the environment include exacerbating the effects of climate change, affecting animal health and reducing microbial diversity in essential reservoirs for ecosystem functioning such as soil.3 Approaches to addressing AMR often focus on either innovation (development of new antibiotics or alternative therapies) or stewardship (optimising use of antimicrobials). However, concerns have been raised about the injustices associated with some stewardship measures. Often, the people whose suboptimal consumption of antibiotics is targeted through stewardship measures are those who are most disadvantaged, for example, low-income parents looking for antibiotics for their children. There are clear ethical tensions between these groups’ interests and those of the general (present and future) population.4
- 3 August 2025
- Published by BMJ in BMJ Global Health
- Vol. 10 (8) , e018943
Open AccessA just war on bugs? Ethical differences between antimalarial resistance and antibacterial resistance
Antimicrobial resistance (AMR) refers to the ability of microbes—bacteria, viruses, fungi and parasites—to survive exposure to drugs that previously cleared them. Mostly, assessments of AMR in research papers and high-level policy documents focus on antibacterial resistance (ABR), sidelining viruses, fungi and parasites. For instance, we know that in 2019 ABR caused around 1.27 million deaths and was associated with 4.95 million deaths. 1 We do not know how many further deaths were associated with or attributable to fungal, parasitic or viral AMR. AMR has negative implications for humans, animals and the environment, including increased morbidity and mortality and unbalanced ecosystems.2 AMR’s effects in the environment include exacerbating the effects of climate change, affecting animal health and reducing microbial diversity in essential reservoirs for ecosystem functioning such as soil.3 Approaches to addressing AMR often focus on either innovation (development of new antibiotics or alternative therapies) or stewardship (optimising use of antimicrobials). However, concerns have been raised about the injustices associated with some stewardship measures. Often, the people whose suboptimal consumption of antibiotics is targeted through stewardship measures are those who are most disadvantaged, for example, low-income parents looking for antibiotics for their children. There are clear ethical tensions between these groups’ interests and those of the general (present and future) population.4
- Open Access
Ethics of Identifying Individuals Involved in HIV Transmission Events by Phylogenetics in Molecular Surveillance
Molecular HIV surveillance, involving the collection and analysis of HIV genome sequences, has become an integral part of public health programmes in high‐income countries. By employing phylogenetic analysis, molecular HIV surveillance can identify individuals and their positions within networks of HIV transmission. While the primary aim of molecular surveillance is to yield public health benefits, such as linking people to care and reducing transmission, it also poses risks and potential infringements on individual privacy and liberty. This paper examines the ethical implications of using phylogenetics to identify individuals involved in multiple transmission events in high‐income countries. Although public health responses tailored to such individuals can significantly reduce further transmission, these individuals often face multiple intersecting vulnerabilities and bear the greatest risks associated with molecular surveillance. We analyze the risks related to privacy, stigma, mistrust, criminalization, and liberty infringements, alongside the benefits of preventing further transmission and increasing healthcare engagement for people living with HIV. We conclude by outlining plausible and ethically acceptable policy options for molecular surveillance practice.
Open AccessEthics of Identifying Individuals Involved in HIV Transmission Events by Phylogenetics in Molecular Surveillance
Molecular HIV surveillance, involving the collection and analysis of HIV genome sequences, has become an integral part of public health programmes in high‐income countries. By employing phylogenetic analysis, molecular HIV surveillance can identify individuals and their positions within networks of HIV transmission. While the primary aim of molecular surveillance is to yield public health benefits, such as linking people to care and reducing transmission, it also poses risks and potential infringements on individual privacy and liberty. This paper examines the ethical implications of using phylogenetics to identify individuals involved in multiple transmission events in high‐income countries. Although public health responses tailored to such individuals can significantly reduce further transmission, these individuals often face multiple intersecting vulnerabilities and bear the greatest risks associated with molecular surveillance. We analyze the risks related to privacy, stigma, mistrust, criminalization, and liberty infringements, alongside the benefits of preventing further transmission and increasing healthcare engagement for people living with HIV. We conclude by outlining plausible and ethically acceptable policy options for molecular surveillance practice.
- 30 April 2025
- Published by Springer Nature in Monash Bioethics Review
- Vol. 43 (2) , 384-397
Coercing for public health: reflections on the role of coercion in public health emergencies
The workshop, Coercing for Health: Transdisciplinary Approaches to the Ethics of Coercive Public Health Policies was held at the University of Oxford on July 3rd and 4th, 2024. This paper provides both a summary of the workshop proceedings and reflections and directions for future research on coercive public health measures. The workshop consisted of four key parts: defining coercion; history and legal analysis of coercion; public health ethics perspectives on coercion; experiences of coercive public health measures. According to our reflections, some important questions remaining for further research include: what is the difference between coercion and enforcement? Who gets to define and address coercion? How do structural factors affect health and experiences of coercion? We encourage others to continue to work on this important area, to ensure the ethically acceptable and thoughtful implementation of any future coercive measures in the sphere of public health.
- 30 April 2025
- Published by Springer Nature in Monash Bioethics Review
- Vol. 43 (2) , 384-397
Coercing for public health: reflections on the role of coercion in public health emergencies
The workshop, Coercing for Health: Transdisciplinary Approaches to the Ethics of Coercive Public Health Policies was held at the University of Oxford on July 3rd and 4th, 2024. This paper provides both a summary of the workshop proceedings and reflections and directions for future research on coercive public health measures. The workshop consisted of four key parts: defining coercion; history and legal analysis of coercion; public health ethics perspectives on coercion; experiences of coercive public health measures. According to our reflections, some important questions remaining for further research include: what is the difference between coercion and enforcement? Who gets to define and address coercion? How do structural factors affect health and experiences of coercion? We encourage others to continue to work on this important area, to ensure the ethically acceptable and thoughtful implementation of any future coercive measures in the sphere of public health.
- Open Access
- 29 April 2025
- Published by Springer Nature in Monash Bioethics Review
- Vol. 43 (2) , 225-228
Coercing for public health: (when) is coercion ethically justified?
- 29 April 2025
- Published by Springer Nature in Monash Bioethics Review
- Vol. 43 (2) , 225-228
Open AccessCoercing for public health: (when) is coercion ethically justified?
- Open Access
- 27 February 2025
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 74 (2) , 001967
Clinical metagenomics: ethical issues
Metagenomics is increasingly used for diagnosis in hospital settings. It is useful particularly in cases of unknown aetiology, where novel or difficult-to-diagnose pathogens are suspected, and/or following unexplained disease outbreaks. In this paper, we present three use cases that draw on existing reports: one involving a patient in intensive care with encephalitis of unknown aetiology; a second case with likely infection with drug-resistant Klebsiella pneumoniae and an incidental finding of unknown relevance; and a third case situated in an unexplained outbreak of acute hepatitis in children, with severe outcomes due to co-infection. We examine each case in turn, highlighting ethical questions arising in relation to clinical issues including: disclosure to patients of untreatable disease, cost-effectiveness, the value of resistance testing, sensitivity and specificity, uncertain or unexpected findings, patient consent and data sharing. We conclude by proposing recommendations for further research and developing particular pieces of guidance to improve clinical uses of metagenomics for diagnosis.
- 27 February 2025
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 74 (2) , 001967
Open AccessClinical metagenomics: ethical issues
Metagenomics is increasingly used for diagnosis in hospital settings. It is useful particularly in cases of unknown aetiology, where novel or difficult-to-diagnose pathogens are suspected, and/or following unexplained disease outbreaks. In this paper, we present three use cases that draw on existing reports: one involving a patient in intensive care with encephalitis of unknown aetiology; a second case with likely infection with drug-resistant Klebsiella pneumoniae and an incidental finding of unknown relevance; and a third case situated in an unexplained outbreak of acute hepatitis in children, with severe outcomes due to co-infection. We examine each case in turn, highlighting ethical questions arising in relation to clinical issues including: disclosure to patients of untreatable disease, cost-effectiveness, the value of resistance testing, sensitivity and specificity, uncertain or unexpected findings, patient consent and data sharing. We conclude by proposing recommendations for further research and developing particular pieces of guidance to improve clinical uses of metagenomics for diagnosis.
- Open Access
- 4 December 2024
- Published by Springer Nature in Monash Bioethics Review
- Vol. 42 (S1) , 1-15
Stewardship and social justice: implications of using the precautionary principle to justify burdensome antimicrobial stewardship measures
Antimicrobial resistance has been termed a ‘silent pandemic’, a ‘hidden killer.’ This language might indicate a threat of significant future harm to humans, animals, and the environment from resistant microbes. If that harm is uncertain but serious, the precautionary principle might apply to the issue, and might require taking ‘precautionary measures’ to avert the threat of antimicrobial resistance, including stewardship interventions like antibiotic prescription caps, bans on certain uses in farming sectors, and eliminating over-the-counter uses of antibiotics. The precautionary principle is a useful tool in ethical analyses of antimicrobial stewardship measures, but as I argue in this article, it ought not be used as a standalone tool. The principle considers the magnitude of harms to be averted and those arising from precautionary measures, but—importantly—it does not consider the distribution of those harms. That may raise issues of social justice if the harms of stewardship measures befall already disadvantaged populations. To avoid this blind spot in ethical analysis using the precautionary principle, it ought never be used alone, but rather always alongside justice-considering ethical concepts such as reciprocity, benefit-sharing, or a just transition.
- 4 December 2024
- Published by Springer Nature in Monash Bioethics Review
- Vol. 42 (S1) , 1-15
Open AccessStewardship and social justice: implications of using the precautionary principle to justify burdensome antimicrobial stewardship measures
Antimicrobial resistance has been termed a ‘silent pandemic’, a ‘hidden killer.’ This language might indicate a threat of significant future harm to humans, animals, and the environment from resistant microbes. If that harm is uncertain but serious, the precautionary principle might apply to the issue, and might require taking ‘precautionary measures’ to avert the threat of antimicrobial resistance, including stewardship interventions like antibiotic prescription caps, bans on certain uses in farming sectors, and eliminating over-the-counter uses of antibiotics. The precautionary principle is a useful tool in ethical analyses of antimicrobial stewardship measures, but as I argue in this article, it ought not be used as a standalone tool. The principle considers the magnitude of harms to be averted and those arising from precautionary measures, but—importantly—it does not consider the distribution of those harms. That may raise issues of social justice if the harms of stewardship measures befall already disadvantaged populations. To avoid this blind spot in ethical analysis using the precautionary principle, it ought never be used alone, but rather always alongside justice-considering ethical concepts such as reciprocity, benefit-sharing, or a just transition.